AMRI
AMRI to Receive Second Milestone Payment from Licensing Agreement with Bristol-Myers Squibb
Published in Medical Letter on the CDC and FDA, June 29th, 2008
AMRI (NASDAQ: AMRI) announced it will receive a $4 million milestone payment from Bristol-Myers Squibb Company (NYSE: BMY) as a result of Bristol-Myers Squibb's submission of a Clinical Trial Application (CTA) to the Health Products and Food Branch (HPFB), Health Canada for approval to initiate Phase I studies on an AMRI compound exclusively licensed to Bristol-Myers Squibb. Upon approval of the CTA by Health Canada, Bristol-Myers Squibb may begin Phase I testing in Canada.
This compound is a biogenic amine reuptake inhibitor acting at multiple targets, which may represent a new class of therapeutic agent that could lead to an improved treatment for depression or other...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
More Articles from Medical Letter on the CDC and FDA
- Norwegian Institute of Public Health
New method identifies rat poison in humans - Artes Medical, Inc.
Dermatologic Surgery Journal Publishes Comparison of Global PMMA-Based Dermal Fillers Showing Superior Characteristics of ArteFill Microspheres - Constipation
Research from College of Medicine in the area of constipation described - IntraHealth International
IntraHealth's Family Planning Work in Rwanda Contributes to Near Three-Fold Increase in Contraceptive Use in Only Three Years - Life Sciences
Data from University of Louisville advance knowledge in life sciences - Psychosis
Research results from Medical University of South Carolina update knowledge of psychosis - More from this issue of Medical Letter on the CDC and FDA
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
